In December 2020, Amgen submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the use in second line of sotorasib in advanced NSCLC patients harboring KRAS G12C mutation. Here, KRAS is linked to non-small cell lung carcinoma.